Shandong Xinhua Pharmaceutical Co., Ltd. (00719): Phenobarbital Tablets Pass Generic Drug Consistency Evaluation

Shandong Xinhua Pharmaceutical Co., Ltd. (00719) announced recently that the company has received the 'Supplementary Drug Application Approval Notice' for phenobarbital tablets issued by the National Medical Products Administration. The product has passed the quality and efficacy consistency evaluation for generic drugs.

Zhitong FinanceMay 18 16:41

H-share Announcements | China Jinmao achieved a cumulative contracted sales amount of 31.234 billion yuan in the first four months, representing a year-on-year increase of 23.44%.

Tuya Inc reported a net profit of US$15.8 million in the first quarter, representing a year-on-year increase of 43.2%. Revenue from its AI business grew by 16.9%, emerging as a new growth driver. China Jinmao achieved cumulative contracted sales of RMB31.234 billion in the first four months, marking a year-on-year increase of 23.44%.

Zhitong FinanceMay 12 09:05

Express News | Xinhua Pharmaceutical: Obtains Drug Registration Certificate for Ambroxol Terol Oral Solution

BreakingsMay 11 16:46

Hong Kong Stock Market Update | Shandong Xinhua Pharmaceutical Co., Ltd. (00719) surged over 7% in the afternoon after its self-developed Benzylhydrazine Hydrochloride API was approved for market release.

Shandong Xinhua Pharmaceutical Co., Ltd. (00719) surged over 7% in the afternoon trading session. As of the time of writing, it had risen by 6.76%, reaching HKD 6.63, with a turnover of HKD 23.1317 million.

Zhitong FinanceMay 11 13:37

H-share announcements | Dama Entertainment issues profit alert, expecting annual net profit attributable to shareholders to be no less than 700 million yuan

Guofu Quantum and Yitusheng Technology have entered into a strategic cooperation memorandum of understanding, planning to jointly establish a quantum computing center in Hong Kong; Dama Entertainment announced a profit alert, expecting its annual net profit attributable to shareholders to be no less than 700 million yuan.

Zhitong FinanceMay 11 09:00

Shandong Xinhua Pharmaceutical Co., Ltd. (00719): Benserazide Hydrochloride Granted Approval Notice for Chemical API Marketing Application

Shandong Xinhua Pharmaceutical Co., Ltd. (00719) announced recently that Shandong Xinhua Pharmaceutical Co., Ltd. (hereinafter referred to as "Xinhua Pharmaceutical" or "the Company") has received the 'Approval Notice for Chemical Raw Material Drug Marketing Application' issued by the National Medical Products Administration for Benserazide Hydrochloride (hereinafter referred to as "this product").

Zhitong FinanceMay 8 16:34